On February 2, 2026, Sangamo Therapeutics reported the termination of their principal financial officer, Prathyusha Duraibabu, and appointed Nikunj Jain as Interim Chief Financial Officer effective February 3, 2026. Additionally, as of December 31, 2025, the company's cash and cash equivalents were approximately $20.9 million, though this figure is subject to change pending audited financial statements.